Highlights of weekly biotech stock moves

Active Biotech AB (SSE:ACTI) fell SEK7.60 (27%) to SEK20.30 on Wednesday after partner Teva Pharmaceutical Industries Ltd. (NASDAQ:TEVA) said it would be "premature" to submit an NDA for laquinimod at this time. Teva, which had planned to submit an NDA early next year, said it will be working with FDA to design an additional trial in relapsing-remitting multiple sclerosis (RRMS). Teva did not disclose a timeline.

Teva has exclusive, worldwide rights to laquinimod from Active. The biotech's shares fell SEK10 (34%) to SEK19.40 for the week. Teva, which made the announcement on its 3Q11 results call, was off $1.41 to $40.93...